39.568 +0.89 (2.31%)
After hours: 4:11PM EDT
|Bid||38.600 x 100|
|Ask||39.050 x 300|
|Day's range||38.150 - 43.100|
|52-week range||11.800 - 49.900|
|PE ratio (TTM)||N/A|
|Earnings date||2 Nov 2017 - 6 Nov 2017|
|Forward dividend & yield||N/A (N/A)|
|1y target est||44.25|
On a per-share basis, the South San Francisco, California-based company said it had a loss of $1.15. For the year, the company reported that its loss widened to $119.5 million, or $4 per share. Atara Biotherapeutics ...
Madrigal (MDGL) has no approved product in its portfolio. So, investors' complete focus on fourth-quarter earnings call will be revolving around the company's lead pipeline candidate, MGL-3196.
Of the six analysts covering Atara Biotherapeutics in January 2018, four analysts have given the stock a “buy” or a higher rating, while two analysts have given it a “hold” rating. By comparison, of the 26 analysts covering Amgen (AMGN) in January 2018, 12 analysts have given the company a “buy” or a higher rating, while 14 analysts have given it a “hold” rating. Of the 31 analysts covering Celgene (CELG) in January 2018, 17 analysts have given the stock a “buy” or a higher rating, while 13 analysts have given the stock a “hold” rating, and only one analyst has given it a “sell” rating.
Jim Cramer listed the J.P. Morgan's Healthcare Conference's best and worst performers judging by the stock market's reaction.
Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a leading off-the-shelf T-cell immunotherapy company developing novel treatments for patients with cancer, autoimmune and viral diseases, today announced that it received clearance of its Investigational New Drug (IND) application from the U.S. Food and Drug Administration (FDA) to proceed with patient enrollment at U.S. sites for its ongoing global Phase 1 clinical study to evaluate ATA188 in patients with progressive or relapsing-remitting multiple sclerosis (MS). ATA188, the Company's off-the-shelf T-cell immunotherapy using a complementary targeted antigen recognition technology licensed from QIMR Berghofer Medical Research Institute, selectively targets specific Epstein-Barr virus (EBV) antigens believed to play an important role in the pathogenesis of MS.
SOUTH SAN FRANCISCO, Calif., Jan. 04, 2018 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a leading off-the-shelf T-cell immunotherapy company developing novel treatments for patients with cancer, autoimmune and viral diseases, today announced that Isaac Ciechanover, M.D., the Company's President and Chief Executive Officer, will present at the 36th Annual J.P. Morgan Healthcare Conference on Tuesday, January 9, 2018, at 3:30 p.m. PST. The conference will be held at the Westin St. Francis Hotel in San Francisco, CA.
Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a leading off-the-shelf T-cell immunotherapy company developing novel treatments for patients with cancer, autoimmune and viral diseases, today announced the pricing of an underwritten public offering of 7,000,000 shares of its common stock at a price to the public of $18.25 per share. In addition, Atara Biotherapeutics has granted the underwriters a 30-day option to purchase up to an additional 1,050,000 shares of its common stock at the public offering price, less the underwriting discounts and commissions. A preliminary prospectus supplement and accompanying prospectus relating to the offering have been filed with the SEC, and a final prospectus supplement and accompanying prospectus related to the offering will be filed with the SEC and will be available on the SEC’s website located at http://www.sec.gov.
– Three clinical sites for both the MATCH and ALLELE pivotal studies now open for enrollment in the U.S. –
Find out how these stocks managed to avoid Friday's minor market slump to end the trading year with a bang.
– Company to announce FDA clearance to initiate two Phase 3 tabelecleucel clinical studies –
Celgene (CELG) owns more than $1.5 billion in shares of more than a dozen smaller drug developers, according to S&P Capital IQ. In December, however, Celgene disclosed in December that it had been cutting back on two positions: CRISPR Therapeutics (CRSP) and Atara Biotherapeutics (ATRA). Celgene, through a subsidiary, cut back on its investment by selling stock in November and December.
On a per-share basis, the South San Francisco, California-based company said it had a loss of $1.02. Atara Biotherapeutics shares have risen 1 percent since the beginning of the year. The stock has fallen ...